Nifty
:
25069.20
Sensex
:
81785.74
-44.80 (-0.18%)
-118.96 (-0.15%)
Nifty
Sensex
:
:
25069.20
81785.74
-44.80 (-0.18%)
-118.96 (-0.15%)

Strides Pharma Science Ltd.

Pharmaceuticals & Drugs - Global

Rating :
68/99

BSE: 532531 | NSE: STAR

NSE BSE
887.45
15-Sep-2025
  • Open
  • High
  • Low
  • Previous Close
  •  909.75
  •  914
  •  884.45
  •  909.75
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  188198
  •  167820363.35
  •  972
  •  513.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 8,179.87
  • 22.54
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 9,838.70
  • 0.45%
  • 3.08

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 28.30%
  • 3.87%
  • 22.11%
  • FII
  • DII
  • Others
  • 28.02%
  • 11.69%
  • 6.01%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.78
  • 6.60
  • 7.37

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.68
  • 4.94
  • 15.67

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.60
  • 2.84
  • 132.95

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.94
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.20
  • 2.48
  • 2.78

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.86
  • 16.18
  • 13.07

Earnings Forecasts:

(Updated: 15-09-2025)
Description
2024
2025
2026
2027
Adj EPS
390.55
51.9
67.8
P/E Ratio
2.27
17.10
13.09
Revenue
4565.33
5075.4
5687.5
EBITDA
802.81
953.7
1100.6
Net Income
3593.45
478.7
624.7
ROA
60.45
P/B Ratio
3.21
2.72
2.31
ROE
153.65
17.1
19.1
FCFF
216.8
490.8
622.9
FCFF Yield
2.22
5.03
6.39
Net Debt
1673.35
BVPS
276.88
326.58
384.36

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Net Sales
1,119.74
1,054.34
6.20%
1,190.39
1,043.50
14.08%
1,153.67
1,005.77
14.71%
1,201.11
999.43
20.18%
Expenses
901.66
864.31
4.32%
972.52
839.19
15.89%
943.35
863.78
9.21%
965.30
846.30
14.06%
EBITDA
218.07
190.03
14.76%
217.87
204.31
6.64%
210.31
141.99
48.12%
235.81
153.13
53.99%
EBIDTM
19.48%
18.02%
18.30%
19.58%
18.23%
14.12%
19.63%
15.32%
Other Income
8.58
12.72
-32.55%
11.98
-13.55
-
5.62
8.75
-35.77%
28.41
35.85
-20.75%
Interest
47.46
72.52
-34.56%
50.32
71.10
-29.23%
52.18
69.71
-25.15%
82.15
78.59
4.53%
Depreciation
48.89
46.52
5.09%
48.86
47.94
1.92%
48.42
49.44
-2.06%
50.52
60.10
-15.94%
PBT
121.94
182.07
-33.03%
103.25
63.66
62.19%
112.89
21.52
424.58%
127.67
-114.64
-
Tax
16.45
19.02
-13.51%
20.76
12.52
65.81%
23.80
15.74
51.21%
21.20
-7.44
-
PAT
105.49
163.06
-35.31%
82.49
51.14
61.30%
89.09
5.78
1,441.35%
106.47
-107.20
-
PATM
9.42%
15.47%
6.93%
4.90%
7.72%
0.57%
8.86%
-10.73%
EPS
10.81
364.62
-97.04%
8.92
1.98
350.51%
9.54
5.41
76.34%
10.14
-14.54
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
4,664.91
4,565.34
3,890.13
3,688.39
3,070.25
3,315.87
2,981.12
3,108.33
3,344.37
3,826.22
2,862.19
Net Sales Growth
13.69%
17.36%
5.47%
20.13%
-7.41%
11.23%
-4.09%
-7.06%
-12.59%
33.68%
 
Cost Of Goods Sold
1,921.30
1,979.96
1,749.05
1,626.88
1,502.32
1,332.79
1,122.48
1,085.20
1,378.84
1,281.17
1,502.29
Gross Profit
2,743.61
2,585.37
2,141.07
2,061.50
1,567.93
1,983.08
1,858.64
2,023.14
1,965.53
2,545.05
1,359.90
GP Margin
58.81%
56.63%
55.04%
55.89%
51.07%
59.81%
62.35%
65.09%
58.77%
66.52%
47.51%
Total Expenditure
3,782.83
3,767.56
3,317.89
3,303.09
3,091.76
2,689.06
2,470.90
2,811.65
3,108.66
3,309.30
2,481.62
Power & Fuel Cost
-
58.17
75.13
85.82
71.54
64.58
64.49
54.39
51.33
33.87
77.18
% Of Sales
-
1.27%
1.93%
2.33%
2.33%
1.95%
2.16%
1.75%
1.53%
0.89%
2.70%
Employee Cost
-
862.76
737.05
732.02
646.91
550.15
442.56
329.44
434.05
419.16
357.69
% Of Sales
-
18.90%
18.95%
19.85%
21.07%
16.59%
14.85%
10.60%
12.98%
10.95%
12.50%
Manufacturing Exp.
-
311.98
299.81
259.45
255.52
237.94
210.79
150.98
115.97
137.47
119.23
% Of Sales
-
6.83%
7.71%
7.03%
8.32%
7.18%
7.07%
4.86%
3.47%
3.59%
4.17%
General & Admin Exp.
-
221.56
198.06
232.21
223.67
191.73
191.89
150.10
194.38
172.63
198.71
% Of Sales
-
4.85%
5.09%
6.30%
7.29%
5.78%
6.44%
4.83%
5.81%
4.51%
6.94%
Selling & Distn. Exp.
-
298.20
215.03
263.65
331.30
223.22
137.07
111.22
208.85
161.12
129.57
% Of Sales
-
6.53%
5.53%
7.15%
10.79%
6.73%
4.60%
3.58%
6.24%
4.21%
4.53%
Miscellaneous Exp.
-
34.93
43.76
103.06
60.51
88.65
301.61
930.33
725.25
1,103.88
129.57
% Of Sales
-
0.77%
1.12%
2.79%
1.97%
2.67%
10.12%
29.93%
21.69%
28.85%
3.39%
EBITDA
882.06
797.78
572.24
385.30
-21.51
626.81
510.22
296.68
235.71
516.92
380.57
EBITDA Margin
18.91%
17.47%
14.71%
10.45%
-0.70%
18.90%
17.12%
9.54%
7.05%
13.51%
13.30%
Other Income
54.59
63.76
49.85
135.22
133.40
59.44
66.70
322.90
920.64
398.08
102.37
Interest
232.11
248.85
280.22
261.14
176.74
150.06
155.72
79.29
196.24
183.10
168.17
Depreciation
196.69
192.26
213.64
243.25
233.01
206.29
187.79
171.85
193.93
198.69
131.25
PBT
465.75
420.42
128.22
16.11
-297.88
329.90
233.42
368.44
766.17
533.20
183.50
Tax
82.21
77.52
29.11
-55.30
-178.26
31.65
17.91
14.49
21.41
51.19
42.45
Tax Rate
17.65%
15.98%
-47.86%
6010.87%
32.91%
8.48%
11.50%
3.71%
2.96%
10.30%
29.87%
PAT
383.54
405.34
-120.20
-221.20
-460.21
352.32
143.62
370.31
681.31
399.38
113.21
PAT before Minority Interest
371.61
409.40
-143.90
-230.90
-474.25
341.61
137.82
375.57
701.18
445.58
99.68
Minority Interest
-11.93
-4.06
23.70
9.70
14.04
10.71
5.80
-5.26
-19.87
-46.20
13.53
PAT Margin
8.22%
8.88%
-3.09%
-6.00%
-14.99%
10.63%
4.82%
11.91%
20.37%
10.44%
3.96%
PAT Growth
240.08%
-
-
-
-
145.31%
-61.22%
-45.65%
70.59%
252.78%
 
EPS
41.60
43.96
-13.04
-23.99
-49.91
38.21
15.58
40.16
73.89
43.32
12.28

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
2,551.83
2,125.57
2,212.26
2,359.23
2,776.66
2,527.42
2,648.70
2,463.66
2,748.82
2,657.87
Share Capital
92.16
91.90
90.30
89.79
89.68
89.56
89.55
89.50
89.42
89.35
Total Reserves
2,459.16
2,030.57
2,102.54
2,266.99
2,682.26
2,432.13
2,551.59
2,365.10
2,650.55
2,562.75
Non-Current Liabilities
601.61
621.44
1,210.30
965.72
1,264.45
813.65
2,342.88
2,067.29
2,048.67
2,760.03
Secured Loans
558.47
618.40
1,040.81
744.86
873.43
601.79
1,806.45
1,551.09
1,622.87
2,614.88
Unsecured Loans
12.78
53.10
98.98
90.77
9.15
2.12
0.06
0.23
14.84
12.13
Long Term Provisions
113.94
91.63
73.42
64.28
246.50
63.95
52.24
16.55
25.19
14.45
Current Liabilities
2,591.52
2,879.26
2,990.20
3,411.68
2,738.35
2,544.86
2,662.24
1,899.30
3,103.87
1,891.98
Trade Payables
1,032.50
851.59
982.34
1,071.52
1,134.20
797.75
888.99
712.07
774.09
775.40
Other Current Liabilities
307.41
341.57
527.89
697.18
421.00
354.49
248.12
129.98
819.08
347.93
Short Term Borrowings
1,136.36
1,574.15
1,330.76
1,496.53
1,023.84
1,228.78
1,339.02
944.39
1,393.96
700.48
Short Term Provisions
115.25
111.94
149.20
146.43
159.31
163.84
186.11
112.86
116.73
68.19
Total Liabilities
5,779.59
5,572.41
6,373.38
6,760.72
6,816.80
5,953.17
7,806.77
6,584.90
8,034.86
7,360.09
Net Block
1,888.12
1,853.18
2,298.42
2,333.45
2,151.13
2,025.85
3,570.13
2,903.00
2,909.03
2,678.68
Gross Block
2,897.25
2,873.18
3,324.82
3,231.69
2,841.28
2,534.38
4,049.05
3,229.03
3,186.12
2,825.43
Accumulated Depreciation
1,009.14
1,020.00
1,026.40
898.24
690.15
508.53
478.92
326.03
277.09
146.75
Non Current Assets
2,680.68
2,603.41
3,130.03
3,398.88
3,999.57
3,581.05
4,758.05
4,101.31
4,243.05
3,845.20
Capital Work in Progress
206.76
161.89
150.98
291.08
447.37
412.95
453.03
620.29
780.18
814.88
Non Current Investment
339.71
196.93
438.96
540.34
666.23
503.24
494.34
350.08
315.66
127.19
Long Term Loans & Adv.
140.19
256.13
217.18
210.58
185.80
210.82
223.69
197.22
222.56
201.83
Other Non Current Assets
94.73
123.38
11.91
10.26
549.04
428.19
16.86
30.72
15.62
22.62
Current Assets
3,098.91
2,969.00
3,135.25
3,361.83
2,817.23
2,372.11
3,048.72
2,483.59
3,791.82
3,514.89
Current Investments
69.50
105.76
50.84
0.00
99.41
118.97
284.75
311.48
1,279.54
1,213.76
Inventories
1,277.57
1,126.24
1,146.51
1,173.80
1,200.70
782.54
874.16
552.02
732.80
613.14
Sundry Debtors
1,202.94
1,141.87
1,299.40
1,207.30
1,110.59
931.69
987.18
882.18
995.91
1,032.97
Cash & Bank
136.78
191.17
315.96
187.35
179.76
237.10
516.65
303.33
329.48
311.59
Other Current Assets
412.12
228.99
169.21
647.90
226.76
301.81
385.98
434.59
454.09
343.44
Short Term Loans & Adv.
135.92
174.97
153.34
145.49
128.54
218.24
249.11
295.75
244.39
97.54
Net Current Assets
507.39
89.74
145.05
-49.84
78.89
-172.75
386.48
584.29
687.95
1,622.91
Total Assets
5,779.59
5,572.41
6,265.28
6,760.71
6,816.80
5,953.16
7,806.77
6,584.90
8,034.87
7,360.09

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
684.37
701.07
44.41
-257.81
481.44
204.79
60.05
187.07
288.14
73.25
PBT
3,675.03
-62.72
-267.63
-652.51
289.38
48.51
344.37
705.80
497.14
146.44
Adjustment
-2,893.97
818.27
682.19
582.27
363.31
527.49
94.59
-274.51
190.92
345.56
Changes in Working Capital
-163.72
-78.73
-457.80
-189.90
-328.05
-326.23
-323.14
-190.66
-341.30
-341.71
Cash after chg. in Working capital
617.34
676.82
-43.23
-260.14
324.64
249.76
115.82
240.63
346.76
150.29
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
67.04
24.25
87.64
2.33
156.80
-44.98
-55.76
-53.56
-58.62
-77.04
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-89.69
-150.25
302.47
-118.73
-520.82
1,306.16
-148.49
582.59
-686.69
-2,224.83
Net Fixed Assets
-32.00
-315.30
-54.00
-61.59
-86.75
-167.06
-48.49
677.20
-236.66
-535.93
Net Investments
515.90
128.18
-92.01
62.72
-219.57
-17.15
-383.09
747.64
-143.27
-1,478.58
Others
-573.59
36.87
448.48
-119.86
-214.50
1,490.37
283.09
-842.25
-306.76
-210.32
Cash from Financing Activity
-642.58
-693.32
-213.92
421.32
-15.80
-1,709.45
194.27
-1,015.69
338.21
2,943.94
Net Cash Inflow / Outflow
-47.90
-142.51
132.96
44.77
-55.18
-198.50
105.83
-246.03
-60.33
792.35
Opening Cash & Equivalents
161.02
303.50
170.73
125.83
182.23
365.89
256.16
515.08
1,110.74
298.91
Closing Cash & Equivalent
112.56
161.02
303.50
170.73
125.83
182.23
365.89
256.16
515.08
1,110.74

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
276.83
230.95
242.83
262.48
309.09
281.55
294.94
274.26
306.41
296.83
ROA
7.21%
-2.41%
-3.52%
-6.99%
5.35%
2.00%
5.22%
9.59%
5.79%
2.03%
ROE
17.52%
-6.67%
-10.15%
-18.49%
12.91%
5.34%
14.74%
27.00%
16.53%
5.25%
ROCE
16.56%
3.47%
-0.49%
-9.49%
11.17%
6.01%
8.65%
16.07%
10.75%
7.54%
Fixed Asset Turnover
2.46
1.96
1.91
1.75
2.04
1.50
1.17
1.04
1.27
1.47
Receivable days
60.35
73.17
73.25
79.41
68.09
70.88
79.95
102.49
96.77
90.73
Inventory Days
61.86
68.12
67.80
81.35
66.13
61.20
61.00
70.11
64.20
52.34
Payable days
173.66
191.36
230.40
267.95
264.54
138.58
146.59
116.23
117.33
75.51
Cash Conversion Cycle
-51.45
-50.07
-89.35
-107.20
-130.32
-6.50
-5.64
56.37
43.64
67.55
Total Debt/Equity
0.70
1.14
1.27
1.18
0.76
0.78
1.22
1.03
1.35
1.34
Interest Cover
2.96
0.59
-0.10
-2.69
3.49
2.00
5.92
4.68
3.71
1.85

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Strides Pharma Science’s arm enters into strategic product development partnership with Kenox
    9th Sep 2025, 09:17 AM

    Strides will collaborate with Kenox on the development and filing of multiple nasal spray products for the US market across diverse therapeutic indications

    Read More
  • Strides Pharma Scien - Quarterly Results
    29th Jul 2025, 12:33 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.